Inactive Instrument

News PreVu, Inc. Other OTC

Equities

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY for the Treatment of Cervical Dystonia	05-10	AQ
U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY for Injection for the Treatment of Cervical Dystonia	23-08-15	AQ
River Hills PreVu, Inc. Went Out of Business	13-09-26	CI
Bankruptcy Court/Judge Changed for River Hills PreVu, Inc.	13-05-20	CI
Bankruptcy Judge Changed for River Hills PreVu, Inc.	12-11-30	CI

No results for this search